Kailera Therapeutics has finished enrolling participants in all three Phase 3 clinical trials for ribupatide, a weekly injection designed to treat obesity. Approximately 4,900 patients have been recruited to undergo testing over a period of about eighteen months. The company, headquartered in Walnut Creek, California, expects to release the final results in mid-2028.
The most anticipated trial is the head-to-head comparison against semaglutide, the current market leader in weight management. This direct competition will determine whether ribupatide can displace an established standard of care. The scale of the study reflects the company’s confidence in its mechanism of action, which targets multiple pathways involved in appetite regulation.
Semaglutide has dominated the obesity drug market since its approval, setting a high bar for efficacy and safety. Kailera’s decision to run a direct comparison signals that ribupatide must match or exceed the performance of the incumbent. The trial design includes primary endpoints for weight loss and secondary endpoints for cardiovascular markers. Participants will receive either ribupatide or semaglutide, with results expected to clarify which molecule offers superior outcomes.
The enrollment phase has concluded, meaning the clinical team is now in the active treatment and follow-up period. Data collection continues through mid-2028, after which the full dataset will be analyzed. Kailera plans to present the findings at a major medical conference before submitting the data to regulatory authorities.
The outcome of the head-to-head trial will directly influence prescribing patterns among endocrinologists and primary care physicians. If ribupatide demonstrates non-inferiority or superiority, it could shift the market share away from semaglutide. Conversely, if it underperforms, the company may need to reposition the drug for specific patient subgroups.
Kailera’s strategy hinges on proving that ribupatide offers a meaningful advantage, whether through greater weight loss, better tolerability, or additional health benefits. The 4,900-patient cohort provides a robust statistical foundation for these claims. Investors and analysts are watching closely, as the results will determine the company’s valuation and potential acquisition interest.
When will the trial results be available? The final data is expected in mid-2028, after the 18-month treatment and follow-up period concludes.
How many patients are enrolled in total? Approximately 4,900 participants have been enrolled across the three Phase 3 trials.
What is the primary competitor being compared? The head-to-head trial directly compares ribupatide against semaglutide, the current market leader in obesity treatment.